+ Follow European Medicines Agency Tag
Array
(
[results] => Array
(
[0] => Array
(
[ArticleID] => 1862098
[Title] => Dengvaxia seen to get EU accreditation
[Summary] => Despite the controversy in the Philippines, Dengvaxia has moved a step closer to becoming the first accredited vaccine against dengue in the European Union (EU).
[DatePublished] => 2018-10-22 00:00:00
[ColumnID] => 0
[Focus] => 1
[AuthorID] => 1804761
[AuthorName] => Helen Flores
[SectionName] => Headlines
[SectionUrl] => headlines
[URL] => http://media.philstar.com/images/articles/gen4-dengvaxia-box-ap_2018-10-21_22-21-29277_thumbnail.jpg
)
[1] => Array
(
[ArticleID] => 1368187
[Title] => AstraZeneca launches breakthrough medication
[Summary] => Recognizing the difficulties being experienced by adult patients with Type 2 diabetes, pharmaceutical company, AstraZeneca, has developed a new oral medication that will aid Filipinos with Diabetes manage their situation better.
[DatePublished] => 2014-09-12 00:00:00
[ColumnID] => 0
[Focus] => 0
[AuthorID] =>
[AuthorName] =>
[SectionName] => Freeman Cebu Business
[SectionUrl] => cebu-business
[URL] =>
)
[2] => Array
(
[ArticleID] => 916465
[Title] => US panel sees risk in long-used osteoporosis drug
[Summary] => A panel of U.S. government health experts says a long-established bone strengthening drug should no longer be used by women because there is little evidence it works and it may actually increase the risk of cancer.
[DatePublished] => 2013-03-06 10:40:17
[ColumnID] => 0
[Focus] => 0
[AuthorID] =>
[AuthorName] =>
[SectionName] => Health And Family
[SectionUrl] => health-and-family
[URL] =>
)
[3] => Array
(
[ArticleID] => 913932
[Title] => Arnold, Mike for affordable health care
[Summary] => Kapuso Network’s Arnold Clavio and Mike Enriquez join RiteMed in its Right to Health campaign to promote access to world-class pharmaceutical and health care products at an affordable cost.
[DatePublished] => 2013-02-28 00:00:00
[ColumnID] => 0
[Focus] => 0
[AuthorID] =>
[AuthorName] =>
[SectionName] => Entertainment
[SectionUrl] => entertainment
[URL] =>
)
[4] => Array
(
[ArticleID] => 833899
[Title] => Novartis cancer drug gets Phl FDA approval
[Summary] => The Novartis anti-cancer drug everolimus, in combination with aromatase inhibitor, is now approved in the Philippines for the treatment of hormone receptor-positive (HR+), HER2/neu-negative (HER2-) advanced breast cancer, in postmenopausal women after recurrence or progression following endocrine therapy.
[DatePublished] => 2012-08-02 00:00:00
[ColumnID] => 133272
[Focus] => 0
[AuthorID] =>
[AuthorName] =>
[SectionName] => Science and Environment
[SectionUrl] => science-and-environment
[URL] =>
)
[5] => Array
(
[ArticleID] => 830068
[Title] => European regulator: Gene therapy treatment OK
[Summary] => The European Medicines Agency is recommending the first-ever approval of a gene therapy treatment in the EU, in a significant move for a type of treatment that has so far failed to deliver on its promise to cure diseases.
[DatePublished] => 2012-07-21 07:00:00
[ColumnID] => 133272
[Focus] => 0
[AuthorID] =>
[AuthorName] =>
[SectionName] =>
[SectionUrl] =>
[URL] =>
)
[6] => Array
(
[ArticleID] => 755739
[Title] => Implications of biosimilars in clinical practice tackled
[Summary] => Pharmaceutical company Roche recently conducted a medical symposium where it invited doctors from various specialties such as medical oncology, rheumatology, endocrinology, gastroenterology, and nephrology for a scientific meeting about the opportunities and challenges of biotherapeutics in clinical practices.
[DatePublished] => 2011-12-08 00:00:00
[ColumnID] => 133272
[Focus] => 0
[AuthorID] =>
[AuthorName] =>
[SectionName] => Science and Environment
[SectionUrl] => science-and-environment
[URL] =>
)
[7] => Array
(
[ArticleID] => 746003
[Title] => SmokeLess passes strict European standards on organic drugs
[Summary] => While most herbal drugs maintain its label of “no therapeutic claims,” Neuravena, the main, active ingredient of SmokeLess, however, has been given a seal of approval from the European Medicines Agency (EMA), a decentralized body of the European Union that is regarded as having one of the most stringent and highest-quality standards among developed countries.
[DatePublished] => 2011-11-10 00:00:00
[ColumnID] => 133272
[Focus] => 0
[AuthorID] =>
[AuthorName] =>
[SectionName] => Science and Environment
[SectionUrl] => science-and-environment
[URL] =>
)
[8] => Array
(
[ArticleID] => 653470
[Title] => Early success of Roche drug vs lung cancer cited
[Summary] => SWITZERLAND — Roche announced this week that an independent data monitoring committee has recommended that the phase III EURTAC study be stopped early because the study has met its primary endpoint.
[DatePublished] => 2011-02-03 00:00:00
[ColumnID] => 133272
[Focus] => 0
[AuthorID] =>
[AuthorName] =>
[SectionName] => Science and Environment
[SectionUrl] => science-and-environment
[URL] =>
)
[9] => Array
(
[ArticleID] => 632713
[Title] => Roche gets license for EGFR lung cancer assay
[Summary] => Roche announced recently that it has obtained a worldwide sub-license from Genzyme Corp. to develop a diagnostic assay for the detection of Epidermal Growth-Factor Receptor (EGFR) mutations.
[DatePublished] => 2010-11-25 00:00:00
[ColumnID] => 133272
[Focus] => 0
[AuthorID] =>
[AuthorName] =>
[SectionName] => Science and Environment
[SectionUrl] => science-and-environment
[URL] =>
)
)
)
European Medicines Agency
Array
(
[results] => Array
(
[0] => Array
(
[ArticleID] => 1862098
[Title] => Dengvaxia seen to get EU accreditation
[Summary] => Despite the controversy in the Philippines, Dengvaxia has moved a step closer to becoming the first accredited vaccine against dengue in the European Union (EU).
[DatePublished] => 2018-10-22 00:00:00
[ColumnID] => 0
[Focus] => 1
[AuthorID] => 1804761
[AuthorName] => Helen Flores
[SectionName] => Headlines
[SectionUrl] => headlines
[URL] => http://media.philstar.com/images/articles/gen4-dengvaxia-box-ap_2018-10-21_22-21-29277_thumbnail.jpg
)
[1] => Array
(
[ArticleID] => 1368187
[Title] => AstraZeneca launches breakthrough medication
[Summary] => Recognizing the difficulties being experienced by adult patients with Type 2 diabetes, pharmaceutical company, AstraZeneca, has developed a new oral medication that will aid Filipinos with Diabetes manage their situation better.
[DatePublished] => 2014-09-12 00:00:00
[ColumnID] => 0
[Focus] => 0
[AuthorID] =>
[AuthorName] =>
[SectionName] => Freeman Cebu Business
[SectionUrl] => cebu-business
[URL] =>
)
[2] => Array
(
[ArticleID] => 916465
[Title] => US panel sees risk in long-used osteoporosis drug
[Summary] => A panel of U.S. government health experts says a long-established bone strengthening drug should no longer be used by women because there is little evidence it works and it may actually increase the risk of cancer.
[DatePublished] => 2013-03-06 10:40:17
[ColumnID] => 0
[Focus] => 0
[AuthorID] =>
[AuthorName] =>
[SectionName] => Health And Family
[SectionUrl] => health-and-family
[URL] =>
)
[3] => Array
(
[ArticleID] => 913932
[Title] => Arnold, Mike for affordable health care
[Summary] => Kapuso Network’s Arnold Clavio and Mike Enriquez join RiteMed in its Right to Health campaign to promote access to world-class pharmaceutical and health care products at an affordable cost.
[DatePublished] => 2013-02-28 00:00:00
[ColumnID] => 0
[Focus] => 0
[AuthorID] =>
[AuthorName] =>
[SectionName] => Entertainment
[SectionUrl] => entertainment
[URL] =>
)
[4] => Array
(
[ArticleID] => 833899
[Title] => Novartis cancer drug gets Phl FDA approval
[Summary] => The Novartis anti-cancer drug everolimus, in combination with aromatase inhibitor, is now approved in the Philippines for the treatment of hormone receptor-positive (HR+), HER2/neu-negative (HER2-) advanced breast cancer, in postmenopausal women after recurrence or progression following endocrine therapy.
[DatePublished] => 2012-08-02 00:00:00
[ColumnID] => 133272
[Focus] => 0
[AuthorID] =>
[AuthorName] =>
[SectionName] => Science and Environment
[SectionUrl] => science-and-environment
[URL] =>
)
[5] => Array
(
[ArticleID] => 830068
[Title] => European regulator: Gene therapy treatment OK
[Summary] => The European Medicines Agency is recommending the first-ever approval of a gene therapy treatment in the EU, in a significant move for a type of treatment that has so far failed to deliver on its promise to cure diseases.
[DatePublished] => 2012-07-21 07:00:00
[ColumnID] => 133272
[Focus] => 0
[AuthorID] =>
[AuthorName] =>
[SectionName] =>
[SectionUrl] =>
[URL] =>
)
[6] => Array
(
[ArticleID] => 755739
[Title] => Implications of biosimilars in clinical practice tackled
[Summary] => Pharmaceutical company Roche recently conducted a medical symposium where it invited doctors from various specialties such as medical oncology, rheumatology, endocrinology, gastroenterology, and nephrology for a scientific meeting about the opportunities and challenges of biotherapeutics in clinical practices.
[DatePublished] => 2011-12-08 00:00:00
[ColumnID] => 133272
[Focus] => 0
[AuthorID] =>
[AuthorName] =>
[SectionName] => Science and Environment
[SectionUrl] => science-and-environment
[URL] =>
)
[7] => Array
(
[ArticleID] => 746003
[Title] => SmokeLess passes strict European standards on organic drugs
[Summary] => While most herbal drugs maintain its label of “no therapeutic claims,” Neuravena, the main, active ingredient of SmokeLess, however, has been given a seal of approval from the European Medicines Agency (EMA), a decentralized body of the European Union that is regarded as having one of the most stringent and highest-quality standards among developed countries.
[DatePublished] => 2011-11-10 00:00:00
[ColumnID] => 133272
[Focus] => 0
[AuthorID] =>
[AuthorName] =>
[SectionName] => Science and Environment
[SectionUrl] => science-and-environment
[URL] =>
)
[8] => Array
(
[ArticleID] => 653470
[Title] => Early success of Roche drug vs lung cancer cited
[Summary] => SWITZERLAND — Roche announced this week that an independent data monitoring committee has recommended that the phase III EURTAC study be stopped early because the study has met its primary endpoint.
[DatePublished] => 2011-02-03 00:00:00
[ColumnID] => 133272
[Focus] => 0
[AuthorID] =>
[AuthorName] =>
[SectionName] => Science and Environment
[SectionUrl] => science-and-environment
[URL] =>
)
[9] => Array
(
[ArticleID] => 632713
[Title] => Roche gets license for EGFR lung cancer assay
[Summary] => Roche announced recently that it has obtained a worldwide sub-license from Genzyme Corp. to develop a diagnostic assay for the detection of Epidermal Growth-Factor Receptor (EGFR) mutations.
[DatePublished] => 2010-11-25 00:00:00
[ColumnID] => 133272
[Focus] => 0
[AuthorID] =>
[AuthorName] =>
[SectionName] => Science and Environment
[SectionUrl] => science-and-environment
[URL] =>
)
)
)
abtest
September 12, 2014 - 12:00am
February 28, 2013 - 12:00am
December 8, 2011 - 12:00am
November 10, 2011 - 12:00am
February 3, 2011 - 12:00am
November 25, 2010 - 12:00am
